Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. - Test2 - elhamkhani - TriplyDB

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

http://www.wikidata.org/entity/Q34045104

about

Oncolytic virotherapy using herpes simplex virus: how far have we come?Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Oncolytic viruses as anticancer vaccines Trial Watch-Oncolytic viruses and cancer therapy Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation A new strategy to ERADicate HER2-positive breast tumors?Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1 Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.Oncolytic virotherapy for head and neck cancer: current research and future developments.Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification.

P2860

Q26862461-55B6347B-753B-48F0-8B79-B31E75418992 Q26863779-FED5AB06-5CB6-49CE-B6C7-25CDBB3D654F Q27025600-715F4E92-81B6-41E4-8DE0-76762DB3F29E Q28072347-F487AAD2-D330-4457-B18B-3EDFB1757C6A Q33566511-9EC128D2-120E-4886-82E5-7E4CA93EAB53 Q35789276-B7266565-E881-4D17-9E2A-A7FC281FA9BB Q36582828-61F07790-4330-4A6E-99E4-C56F283B0BD5 Q38795324-6ECC727D-FDFA-4B60-B2A6-3FF62D798B20 Q38799515-10A05680-664D-4CAD-BB3D-685734A2B0D4 Q38924562-19CBEBB2-46BC-4F28-B53B-5C8247C64E8E Q40072916-8BE6C1F2-826B-4DA8-B29F-C95596AF4BD3 Q40081751-E0BBD212-7E1E-4233-B4DA-3B36907B0078 Q40471303-EC44F8A0-9877-4E09-8940-2396447F36A8 Q40498974-CAF6A7EE-02F2-4F25-AFF5-CA6AF185F575 Q41863613-341CF071-EC46-4669-8885-06167606E139 Q48000346-BD0639C2-7BAD-497C-949D-7D50C0E8B512 Q48227188-6D85C48A-6291-4ABB-9CA2-15806AD5CFC4 Q48678461-989F166B-AC0A-4FF3-9A1A-3302C7C9267E Q52312118-BF699B38-49F2-4D0A-9707-E85539A062E4 Q55416886-B76BCE74-D7DA-4F7B-BF8F-509452EAEE9D

P2860

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

http://www.wikidata.org/entity/Q34045104

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@ast

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@en

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@nl

type

label

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@ast

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@en

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@nl

prefLabel

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@ast

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@en

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@nl

P1433

Q34045104-3D0D8233-EF42-4E31-9F52-141B91C0BE4A

P1476

Q34045104-14A77977-95FA-4B07-A88F-3649D57CD3F1

P2093

Q34045104-26147AB3-101B-4158-AECF-61D6E2BD6F5F

Q34045104-2B966F5E-76EF-423C-9D75-077D934B2EDC

Q34045104-44184533-47F9-4789-9B69-64105A27FEA9

Q34045104-4FB23F67-680E-4C30-9BD5-E355C9145053

Q34045104-54D2C4F8-C2E6-4913-9D26-3B0D2D12E53F

Q34045104-5DDB43FF-0318-4574-B90E-7A229D990250

Q34045104-66C63B57-65DA-462E-BD20-5A83D0D0848C

Q34045104-7BA6C2F6-080E-4990-9D53-A462E4CCBBEB

Q34045104-7F1F1D02-227C-4AB4-BA4A-3B1CD449D8AB

Q34045104-913DC146-4B81-4B60-8D18-A7BEFFEE233A

P2860

Q34045104-06C2D376-F9DD-44CF-B3D3-1AFD15304FFA

Q34045104-0E61CC1A-13E9-4DDE-A8D8-0721C0B2E80E

Q34045104-195634FE-CD71-4BD8-A006-E9C3DB6CF5F4

Q34045104-1BF50654-DFBA-46B7-AA90-73321682BF35

Q34045104-304D611A-A799-47DE-BBF3-8BA7CB0648C0

Q34045104-3C36F659-5BED-4F1A-A417-4CB602EA8F26

Q34045104-488A929C-80BA-4518-8BC8-F38A45B1BC93

Q34045104-517E9189-BC15-460C-BA12-7D78C8AE2A97

Q34045104-56AD2322-277A-45EE-B270-569665B7AF73

Q34045104-59115679-2743-4BEE-8B70-F8849B97D247

P304

Q34045104-33157FAA-50DA-4727-8E37-CF47CA0757E9

P31

Q34045104-AAB1492A-980B-4120-990D-B31849EC2040

P356

Q34045104-C37616B6-D3E0-4C2A-8D24-2BF1FF8C3AA9

P407

Q34045104-BDC1E9FC-1F7F-4AD2-B44D-690E1CD6139C

P433

Q34045104-E51B5625-CB4F-415E-8B04-194F987F90CA

P478

Q34045104-137D17EE-8907-41DF-95C0-5ED077BF7E53

P577

Q34045104-74351301-3F4A-41A4-9D71-055659377187

P698

Q34045104-271606EA-93B3-4DFE-9FEA-473763AAA57C

P932

Q34045104-804FBE35-849F-4628-AA7F-2CFC977C2665

P356

1078-0432.CCR-14-0553

P1433

Clinical Cancer Research

P1476

Bortezomib-induced unfolded pr ...... synergistic antitumor effects.

@en

P2093

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

Brian S Hurwitz

http://www.w3.org/2001/XMLSchema#string

Chelsea Bolyard

http://www.w3.org/2001/XMLSchema#string

David Eaves

http://www.w3.org/2001/XMLSchema#string

Deborah S Parris

http://www.w3.org/2001/XMLSchema#string

Ji Young Yoo

http://www.w3.org/2001/XMLSchema#string

Jianhua Yu

http://www.w3.org/2001/XMLSchema#string

Jianying Zhang

http://www.w3.org/2001/XMLSchema#string

Jun-Ge Yu

http://www.w3.org/2001/XMLSchema#string

Karuppaiyah Selvendiran

http://www.w3.org/2001/XMLSchema#string

P2860

A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Nuclear sequestration of cellular chaperone and proteasomal machinery during herpes simplex virus type 1 infection

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

Herpes simplex virus oncolytic therapy for pediatric malignancies

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies

Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1.

Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.

A pre-immediate-early role for tegument ICP0 in the proteasome-dependent entry of herpes simplex virus

P304

3787-3798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-0553

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24815720

http://www.w3.org/2001/XMLSchema#string

P932

4132885

http://www.w3.org/2001/XMLSchema#string